ARC-7
10 Nov 2020
ARC-7
NCT04262856
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer.
Arcus Biosciences, Inc.
Cancer Type | Lung & mesothelioma |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2020-05-28 |
Anticipated End Date | 2023-06-23 |
Hospital | Calvary Central Districts Hospital |
---|---|
Clinical Trial Coordinator | Julie Rowe |
julie.rowe@calvarycare.org.au | |
Phone | 08 8239 9536 |
Principal Investigator | Dr Rohit Joshi |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs